ACADIA Pharmaceuticals Management
Management criteria checks 4/4
ACADIA Pharmaceuticals' CEO is Steve Davis, appointed in Sep 2015, has a tenure of 8.67 years. total yearly compensation is $7.59M, comprised of 11.3% salary and 88.7% bonuses, including company stock and options. directly owns 0.094% of the company’s shares, worth $2.64M. The average tenure of the management team and the board of directors is 2.3 years and 8.6 years respectively.
Key information
Steve Davis
Chief executive officer
US$7.6m
Total compensation
| CEO salary percentage | 11.3% |
| CEO tenure | 8.7yrs |
| CEO ownership | 0.09% |
| Management average tenure | 2.3yrs |
| Board average tenure | 8.6yrs |
Recent management updates
Recent updates
ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Price Is Right But Growth Is Lacking
Apr 24
We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Mar 27Acadia Pharmaceuticals: Post Pimavanserin Study Setback Selloff May Continue
Mar 12ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Just Released Its Full-Year Earnings: Here's What Analysts Think
Mar 01Acadia Pharmaceuticals: New Daybue Drug Already Showing Signs Of Slowing
Feb 29Soleno Therapeutics And Acadia Pharmaceuticals: Hope For Prader-Willi Families
Jan 23ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
Jan 03We're Interested To See How ACADIA Pharmaceuticals (NASDAQ:ACAD) Uses Its Cash Hoard To Grow
Dec 04Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share Price
May 22Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last Hurrah
Oct 19FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetide
Sep 12Acadia: Powerful Unfolding Catalysts
Aug 03Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndrome
Jul 18FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run Yet
Jun 29Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In Growth
May 07Acadia: Catalysts Stacking
Apr 28Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's Right
Feb 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$8m | US$857k | -US$61m |
| Sep 30 2023 | n/a | n/a | -US$149m |
| Jun 30 2023 | n/a | n/a | -US$111m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$14m | US$822k | -US$216m |
| Sep 30 2022 | n/a | n/a | -US$217m |
| Jun 30 2022 | n/a | n/a | -US$205m |
| Mar 31 2022 | n/a | n/a | -US$214m |
| Dec 31 2021 | US$10m | US$793k | -US$168m |
| Sep 30 2021 | n/a | n/a | -US$192m |
| Jun 30 2021 | n/a | n/a | -US$262m |
| Mar 31 2021 | n/a | n/a | -US$260m |
| Dec 31 2020 | US$8m | US$768k | -US$282m |
| Sep 30 2020 | n/a | n/a | -US$268m |
| Jun 30 2020 | n/a | n/a | -US$225m |
| Mar 31 2020 | n/a | n/a | -US$238m |
| Dec 31 2019 | US$8m | US$744k | -US$235m |
| Sep 30 2019 | n/a | n/a | -US$248m |
| Jun 30 2019 | n/a | n/a | -US$268m |
| Mar 31 2019 | n/a | n/a | -US$276m |
| Dec 31 2018 | US$7m | US$720k | -US$245m |
| Sep 30 2018 | n/a | n/a | -US$249m |
| Jun 30 2018 | n/a | n/a | -US$252m |
| Mar 31 2018 | n/a | n/a | -US$256m |
| Dec 31 2017 | US$15m | US$700k | -US$289m |
Compensation vs Market: Steve's total compensation ($USD7.59M) is about average for companies of similar size in the US market ($USD6.67M).
Compensation vs Earnings: Steve's compensation has been consistent with company performance over the past year.
CEO
Steve Davis (62 yo)
8.7yrs
Tenure
US$7,587,014
Compensation
Mr. Stephen R. Davis, also known as Steve, J. D. served as the Director at Heron Therapeutics Inc. since September 2019 until February 21, 2023. He has been the Chief Executive Officer of ACADIA Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.7yrs | US$7.59m | 0.094% $ 2.6m | |
| Executive VP & CFO | 2.7yrs | US$2.59m | 0.019% $ 544.8k | |
| Executive VP | 2.5yrs | US$2.62m | 0.025% $ 716.2k | |
| VP, Chief Accounting Officer & Corporate Controller | 3.8yrs | no data | 0.0087% $ 244.3k | |
| Executive VP and Head of Research & Development | less than a year | no data | no data | |
| Senior Vice President of Technical Development & Operations | 1.5yrs | no data | no data | |
| Senior Vice President of Investor Relations & Corporate Communications | less than a year | no data | no data | |
| Executive VP | less than a year | no data | no data | |
| Senior Vice President of Marketing & Commercial Strategy | 2.5yrs | no data | no data | |
| Senior VP & Head of Sales | 2.3yrs | no data | no data | |
| Senior VP & Chief People Officer | 2.3yrs | no data | no data | |
| Senior Vice President of New Product Planning & Strategy | no data | no data | no data |
2.3yrs
Average Tenure
51yo
Average Age
Experienced Management: ACAD's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.7yrs | US$7.59m | 0.094% $ 2.6m | |
| Independent Director | 16yrs | US$392.75k | 0.0082% $ 229.5k | |
| Independent Director | 8.4yrs | US$377.75k | 0.062% $ 1.7m | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 8.5yrs | US$387.75k | 0.011% $ 323.0k | |
| Independent Director | 9.2yrs | US$387.75k | 0.017% $ 476.0k | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Member of the Scientific and Clinical Advisory Board | no data | no data | no data | |
| Independent Director | 8.3yrs | US$387.75k | 0.011% $ 306.1k | |
| Independent Chairman of the Board | 11.3yrs | US$432.75k | 0.062% $ 1.7m | |
| Independent Director | 3.7yrs | US$377.75k | 0.0096% $ 269.6k |
8.6yrs
Average Tenure
65yo
Average Age
Experienced Board: ACAD's board of directors are considered experienced (8.6 years average tenure).